Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for melanomaAnnounced gonorrhea as second bacterial product
COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered